Clinical Trials Browser

Lymphoma, B-Cell, Marginal Zone

Hodgkin Disease, Lymphoma, B-Cell

Lymphoma, Mantle-Cell

Recurrence, Lymphoma, Mantle-Cell

Multiple Myeloma

Lymphoma, B-Cell, Marginal Zone

Leukemia, Plasma Cell

Multiple Myeloma

Lymphoma, Mantle-Cell

Multiple Myeloma

Lymphoma, Follicular

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Heart Failure, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating, Cardiotoxicity

Amyloidosis, Multiple Myeloma, Neoplasm, Residual

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

Multiple Myeloma

Multiple Myeloma

Lymphoma, B-Cell, Marginal Zone

Lymphoma, Large B-Cell, Diffuse

Leukemia, Plasma Cell, Multiple Myeloma

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Multiple Myeloma

Multiple Myeloma, Neoplasms, Peripheral Nervous System Diseases

Multiple Myeloma

Lymphoma, B-Cell, Marginal Zone

Multiple Myeloma, Neoplasms

Multiple Myeloma

Multiple Myeloma

Lymphoma, B-Cell

Lymphoma, Large B-Cell, Diffuse

Multiple Myeloma

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

Lymphoma, Non-Hodgkin

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

Recurrence, Lymphoma, Large B-Cell, Diffuse

Multiple Myeloma

Lymphoma, Recurrence, Neoplasm, Residual

Smoldering Multiple Myeloma, Multiple Myeloma

Multiple Myeloma

Multiple Myeloma, Vitamin D Deficiency

Neoplasms, Plasma Cell

Multiple Myeloma, Neoplasm, Residual

Lymphoma, Mantle-Cell

Lymphoma, Follicular

Lymphoma, Large B-Cell, Diffuse

Multiple Myeloma

Clinical Trials

MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma

Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL

A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia

HEME-18

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma

FASTER

MASTER-2

Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse

Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma

HO170DLBCL

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma

HD10/DSMMXX

MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

UltraFrailMM

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients

VRd MM Fibrate

ERd Combination Treatment in Newly Diagnosed Multiple Myeloma

Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

IFM2021-01

Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma

JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma

Pola-ZR2P in Previously Untreated DLBCL

SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease

REPIFIR

MTR²

HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL

Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

EpLCART

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

VitD3 Supplementation in Patients With Multiple Myeloma

SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II Trial

Risk Stratification and MRD-driven Maintenance for MM After ASCT

V-MIND

MorningLyte

Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL

HOVON174MM